Drug Modalities

Pharma R&D bucketed by therapeutic modality: biologics, monoclonal antibodies, small molecules, ADCs, cell therapy (CAR-T), gene therapy, gene editing (CRISPR), mRNA, siRNA, ASO, bispecifics, vaccines. Each modality has its own pipeline view, sponsor landscape, and RSS feed.

Pharma R&D split by the underlying biophysical class of the drug. Each modality has different manufacturing footprint, IP landscape, regulatory pathway, and BD economics. Click into any modality for the full pipeline view, recent approvals, sponsor landscape, and RSS feed.

Protein

• Biologics Landing RSS
  mAbs, recombinant proteins, peptides
• Monoclonal Antibodies Landing RSS
  mAbs across oncology, immunology, infectious disease
• Bispecific Antibodies Landing RSS
  T-cell engagers and dual-target antibodies
• Antibody-Drug Conjugates Landing RSS
  Targeted cytotoxic payload delivery

Chemical

• Small Molecules Landing RSS
  Traditional oral / IV chemical entities

Advanced

• Cell Therapies Landing RSS
  CAR-T, TCR, TILs, NK cells
• Gene Therapies Landing RSS
  AAV / lentiviral genetic correction
• Gene Editing Landing RSS
  CRISPR / base / prime editing

Nucleic

• mRNA Therapeutics Landing RSS
  mRNA-LNP delivery, vaccines + therapeutics
• siRNA Therapeutics Landing RSS
  GalNAc-conjugated RNAi for liver-targeted disease
• Antisense Oligonucleotides Landing RSS
  ASO mRNA-modulating therapeutics

Vaccine

• Vaccines Landing RSS
  Prophylactic and therapeutic vaccines

Related landings

• Therapeutic areas — pipeline by disease bucket
• CI briefs — competitive intel by drug / disease / company
• Today in pharma — live event view
• Build a custom RSS feed